Nifty
Sensex
:
:
11095.25
37687.91
203.65 (1.87%)
748.31 (2.03%)

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 500124 | NSE: DRREDDY

4527.45
03-Aug-2020
  • Open
  • High
  • Low
  • Previous Close
  •  4521.05
  •  4670.00
  •  4500.00
  •  4521.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2436651
  •  111624.10
  •  4670.00
  •  2351.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 75,205.25
  • 38.68
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 77,210.15
  • 0.55%
  • 4.68

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.74%
  • 4.92%
  • 7.41%
  • FII
  • DII
  • Others
  • 29.33%
  • 14.41%
  • 17.19%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.86
  • 2.39
  • 7.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.70
  • -7.18
  • 0.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.03
  • -1.34
  • 29.25

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.35
  • 30.78
  • 29.89

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.41
  • 3.76
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.06
  • 17.11
  • 16.07

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
4,426.50
3,858.20
14.73%
4,448.90
4,029.60
10.41%
4,397.10
3,864.60
13.78%
4,812.80
3,817.50
26.07%
Expenses
3,305.20
3,116.50
6.05%
3,499.70
3,210.70
9.00%
4,685.80
3,060.00
53.13%
3,749.00
3,058.20
22.59%
EBITDA
1,121.30
741.70
51.18%
949.20
818.90
15.91%
-288.70
804.60
-
1,063.80
759.30
40.10%
EBIDTM
25.33%
19.22%
21.34%
20.32%
-6.57%
20.82%
22.10%
19.89%
Other Income
87.10
430.10
-79.75%
73.60
83.30
-11.64%
67.30
102.30
-34.21%
54.00
128.20
-57.88%
Interest
23.30
29.80
-21.81%
23.00
24.50
-6.12%
15.20
24.10
-36.93%
30.30
20.80
45.67%
Depreciation
292.30
289.00
1.14%
274.10
287.20
-4.56%
286.90
290.30
-1.17%
313.10
278.60
12.38%
PBT
892.80
853.00
4.67%
725.70
590.50
22.90%
-523.50
592.50
-
774.40
588.10
31.68%
Tax
305.90
192.80
58.66%
-44.90
150.80
-
32.50
101.10
-67.85%
-320.70
80.70
-
PAT
586.90
660.20
-11.10%
770.60
439.70
75.26%
-556.00
491.40
-
1,095.10
507.40
115.83%
PATM
13.26%
17.11%
17.32%
10.91%
-12.64%
12.72%
22.75%
13.29%
EPS
41.07
46.20
-11.10%
53.93
30.77
75.27%
-38.91
34.39
-
76.63
35.51
115.80%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
18,085.30
17,517.00
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
Net Sales Growth
16.16%
13.39%
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
 
Cost Of Goods Sold
5,667.10
5,554.40
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
Gross Profit
12,418.20
11,962.60
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
GP Margin
68.66%
68.29%
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
Total Expenditure
15,239.70
15,046.60
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
Power & Fuel Cost
-
314.80
329.10
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
% Of Sales
-
1.80%
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
Employee Cost
-
3,380.20
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
% Of Sales
-
19.30%
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
Manufacturing Exp.
-
1,445.40
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
% Of Sales
-
8.25%
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
General & Admin Exp.
-
1,195.20
1,143.70
1,193.40
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
% Of Sales
-
6.82%
7.40%
8.36%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
Selling & Distn. Exp.
-
1,408.30
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
% Of Sales
-
8.04%
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
Miscellaneous Exp.
-
1,748.30
87.90
76.00
70.60
483.00
65.70
35.60
38.50
85.20
744.90
% Of Sales
-
9.98%
0.57%
0.53%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
EBITDA
2,845.60
2,470.40
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
EBITDA Margin
15.73%
14.10%
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
Other Income
282.00
620.60
337.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
Interest
91.80
98.30
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
Depreciation
1,166.40
1,163.10
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
PBT
1,869.40
1,829.60
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
Tax
-27.20
-140.30
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
Tax Rate
-1.46%
-7.67%
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
PAT
1,896.60
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
PAT before Minority Interest
1,896.60
1,969.90
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
10.49%
11.25%
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
PAT Growth
-9.63%
3.34%
108.92%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
 
EPS
132.72
137.85
133.39
63.85
87.98
147.49
163.50
137.38
106.84
91.04
69.90

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
15,598.80
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
Share Capital
83.10
83.00
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
Total Reserves
15,411.90
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
Non-Current Liabilities
-807.50
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
Secured Loans
130.40
55.20
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
Unsecured Loans
0.00
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
Long Term Provisions
74.50
79.30
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
Current Liabilities
7,214.10
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
Trade Payables
1,524.80
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
Other Current Liabilities
3,512.00
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
Short Term Borrowings
1,653.20
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
Short Term Provisions
524.10
497.00
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
Total Liabilities
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
Net Block
6,850.30
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
Gross Block
19,335.50
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
Accumulated Depreciation
12,146.40
10,845.80
10,468.30
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
Non Current Assets
9,406.30
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
Capital Work in Progress
1,535.10
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
Non Current Investment
309.10
334.20
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
Long Term Loans & Adv.
688.70
426.70
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
Other Non Current Assets
23.10
38.40
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
Current Assets
12,599.10
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
Current Investments
2,368.70
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
Inventories
3,506.70
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
Sundry Debtors
5,027.80
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
Cash & Bank
205.30
222.80
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
Other Current Assets
1,490.60
849.80
765.90
451.50
1,115.60
1,231.00
1,214.60
961.90
705.80
879.60
Short Term Loans & Adv.
444.50
439.80
674.10
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
Net Current Assets
5,385.00
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
Total Assets
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
2,984.10
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
PBT
1,885.70
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
Adjustment
2,562.50
1,639.60
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
Changes in Working Capital
-753.60
-577.10
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
Cash after chg. in Working capital
3,694.60
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-710.50
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-492.30
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
Net Fixed Assets
-453.50
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
Net Investments
-1,552.00
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
Others
1,513.20
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
Cash from Financing Activity
-2,515.90
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
Net Cash Inflow / Outflow
-24.10
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
Opening Cash & Equivalents
222.80
254.20
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
Closing Cash & Equivalent
196.20
222.80
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
932.31
840.01
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
ROA
8.95%
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
ROE
13.38%
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
ROCE
10.81%
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
Fixed Asset Turnover
0.94
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
Receivable days
93.92
94.98
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
Inventory Days
71.52
74.03
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
Payable days
39.56
39.46
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
Cash Conversion Cycle
125.88
129.55
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
Total Debt/Equity
0.14
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
Interest Cover
19.61
26.78
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62

News Update:


  • Dr. Reddy's Laboratories reports 12% fall in Q1 consolidated net profit
    30th Jul 2020, 10:35 AM

    Total income of the company increased by 5.25% at Rs 4513.60 crore for Q1FY21

    Read More
  • Dr. Reddy's Laboratories receives approval of XEGLYZE lotion in US
    27th Jul 2020, 13:06 PM

    The company is working to commercialize this product through partners

    Read More
  • Dr. Reddy's Laboratories launches over-the-counter Nicotine Polacrilex Lozenges
    14th Jul 2020, 13:40 PM

    The company’s Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers’ requirements

    Read More
  • Dr. Reddy's expecting overall performance to be quite volatile in current fiscal
    6th Jul 2020, 14:02 PM

    As per the company, overall, there was no major impact of the pandemic during the last fiscal, including the fourth quarter

    Read More
  • Dr Reddy's Laboratories inks pact with FUJIFILM, Global Response Aid
    1st Jul 2020, 13:55 PM

    The company has partnered for the development, manufacture and sales of Avigan Tablets a potential treatment of COVID-19

    Read More
  • Dr Reddy's expects to launch 25 products in US market in FY21
    29th Jun 2020, 09:11 AM

    The drug major has also earmarked a capex of Rs 1,000 crore for finding various projects during the ongoing financial year

    Read More
  • Dr. Reddy's Laboratories working on four new products
    23rd Jun 2020, 16:08 PM

    The new compounds are in the therapeutic areas of paediatrics, dermatology, haematology-oncology

    Read More
  • Dr. Reddy's launches Abiraterone Acetate Tablets in US market
    19th Jun 2020, 14:55 PM

    The company’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120

    Read More
  • Dr. Reddy's enters into licensing agreement with Gilead Sciences
    13th Jun 2020, 14:27 PM

    The company will receive technology transfer from Gilead for manufacturing drug, Remdesivir

    Read More
  • Dr. Reddy's launches Colchicine tablets in US market
    13th Jun 2020, 09:56 AM

    The company's Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s

    Read More
  • Dr. Reddy's completes acquisition of select business divisions of Wockhardt
    11th Jun 2020, 09:05 AM

    The company has completed the acquisition of select divisions of Wockhardt’s branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives

    Read More
  • Dr. Reddy's Lab gets EIR for API Srikakulam Plant in Andhra Pradesh
    1st Jun 2020, 09:38 AM

    The company has received the EIR from the USFDA, indicating that the inspection is closed under 21 CFR 20.64(d)(3)

    Read More
  • Dr. Reddy's Lab gets EIR for Integrated Product Development Organization at Telangana
    28th May 2020, 13:16 PM

    The company has received the Establishment Inspection Report from USFDA

    Read More
  • Dr. Reddy's Lab gets EIR for formulations manufacturing plant in Hyderabad
    20th May 2020, 10:32 AM

    The company has received the EIR from USFDA

    Read More
  • Dr. Reddys Lab - Quarterly Results
    20th May 2020, 12:00 AM

    Read More
  • Dr. Reddy's Lab gets EIR for formulations Srikakulum plant in Andhra Pradesh
    14th May 2020, 10:11 AM

    The inspection classification of this facility is determined as No Action Indicated

    Read More
  • Dr. Reddy's recalling 1,752 bottles of generic heartburn medicine in US
    11th May 2020, 10:19 AM

    The ongoing Class III recall is on account of Discolouration and because the product contains brown pellets

    Read More
  • Dr. Reddy's Lab gets EIR for Andhra Pradesh plant
    8th May 2020, 14:27 PM

    The inspection classification of this facility is determined as Voluntary Action Indicated

    Read More
  • Dr. Reddy's gets USFDA’s nod for migraine treatment oral solution
    7th May 2020, 09:06 AM

    ELYXYB is indicated for the acute treatment of migraine with or without aura in adults

    Read More
  • Dr. Reddy's launches Desmopressin Acetate Injection USP
    6th May 2020, 14:08 PM

    Desmopressin Acetate Injection USP, 4 mcg/mL is available in a carton of ten 1 mL single dose ampules

    Read More
  • Dr Reddy's Laboratories launches Fenofibrate Tablets USP in US Market
    27th Apr 2020, 13:15 PM

    The company’s Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.